Market Overview:
The global NSCLS drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of NSCLS, rising demand for targeted therapies, and growing awareness about lung cancer. Based on type, the global NSCLS drugs market is segmented into EGFR targeting drugs, ALK targeting drugs, PD-1/PD-L1 targeting drugs, gemcitabine-based regimens (cisplatin/carboplatin + pemetrexed or paclitaxel), and other chemotherapeutic agents (paclitaxel + carboplatin or cisplatin). The EGFR targeting drug segment is expected to account for the largest share of the global NSCLS drugs market in 2018. This segment is projected to grow at a CAGR of 8% during the forecast period. The large share of this segment can be attributed to factors such as increasing incidence of EGFR mutation-positive tumors and rising demand for targeted therapies. Based on application, the global NSCLS Drugs Market is divided into four segments: less than or equal to 30 years old; 31 - 45 years old; 46 - 60 years old; and above 60 years old.
Product Definition:
NSCLS Drugs are Non-Small Cell Lung Cancer drugs. These are used to treat cancer that has started in the lungs and has spread to other parts of the body.
EGFR Targeting:
EGFR (Epidermal Growth Factor Receptor) targeting is a new approach to cancer treatment that involves the use of drugs that target EGFR. The main goal of these therapies is to control or reduce tumor growth without affecting normal tissues. These are some of the most effective targeted therapy drugs available today and have been receiving tremendous support from regulatory bodies across the globe.
ALK Targeting:
ALK (Asplenia Lateral Sclerosis) is a rare genetic disorder that leads to the formation of clumps called “lesions” in various parts of the body, such as kidneys, liver and spleen. The most common symptoms include fever, stiffness in muscles, loss of vision and hearing among others.
Application Insights:
The application segment is divided into less than or equal to 30 years old, 31 - 45 years old, 46 - 60 years old and above 60 years old. The less than or equal to 30years olds held the largest share of over 40% in 2017. This can be attributed to the increasing incidence of cancer in this age group across the globe. As per IARC, around 5-10% of people within each generation (i.e., every 2-5 generations) get diagnosed with cancer which amounts to around 50-100 million people globally each year making it one of the most common diseases throughout human history.
The 31 - 45 year olds accounted for a significant share as well as they are getting diagnosed at a faster rate compared to other age groups due their higher risk profile owing to early exposure.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Merck & Co., Inc.; Pfizer, Inc.; and Celgene Corporation; in this region. The U.S.-based companies are engaged in research activities to develop novel drugs for advanced cancers that are resistant to standard treatment options.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure leading towards better diagnosis and treatment of cancer at a domestic level. Moreover, government initiatives encouraging clinical research studies are also anticipated boost regional growth during the forecast period (2018-2030).
Growth Factors:
- Increasing incidence of NSCLS
- Rising demand for better and more effective drugs for the treatment of NSCLS
- Growing awareness about NSCLS and its treatment options
- Technological advancements in the field of lung cancer treatment
- Availability of government funding and support for research on lung cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
NSCLS Drugs Market Research Report
By Type
EGFR Targeting, ALK Targeting, PD-1/PD-L1 Targeting, Gemcitabine, Cisplatin/Carboplatin, Pemetrexed, Paclitaxel, Others, NSCLS Drug
By Application
Less than or equal to 30 Years Old, 31 - 45 Years Old, 46 - 60 Years Old, Above 60 Years Old
By Companies
Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical, Boehringer-Ingelheim, AstraZeneca, Betta Pharmaceuticals, Qilu Oharmaceutical, Pierre Fabre Medicament, Chemo Wanbang Biopharma, Hetero Drugs, Harbin Gloria Pharmaceuticals, Luoxin Pharmaceutical, Teva Pharmaceutical, Mylan, Sun Pharmaceutical, Fosun Pharma, NSCLS Drug
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global NSCLS Drugs Market Report Segments:
The global NSCLS Drugs market is segmented on the basis of:
Types
EGFR Targeting, ALK Targeting, PD-1/PD-L1 Targeting, Gemcitabine, Cisplatin/Carboplatin, Pemetrexed, Paclitaxel, Others, NSCLS Drug
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Less than or equal to 30 Years Old, 31 - 45 Years Old, 46 - 60 Years Old, Above 60 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Novartis
- Pfizer
- Merck
- Bristol-Myers Squibb
- Eli Lilly and Company
- Takeda Pharmaceutical
- Boehringer-Ingelheim
- AstraZeneca
- Betta Pharmaceuticals
- Qilu Oharmaceutical
- Pierre Fabre Medicament
- Chemo Wanbang Biopharma
- Hetero Drugs
- Harbin Gloria Pharmaceuticals
- Luoxin Pharmaceutical
- Teva Pharmaceutical
- Mylan
- Sun Pharmaceutical
- Fosun Pharma
- NSCLS Drug
Highlights of The NSCLS Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- EGFR Targeting
- ALK Targeting
- PD-1/PD-L1 Targeting
- Gemcitabine
- Cisplatin/Carboplatin
- Pemetrexed
- Paclitaxel
- Others
- NSCLS Drug
- By Application:
- Less than or equal to 30 Years Old
- 31 - 45 Years Old
- 46 - 60 Years Old
- Above 60 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the NSCLS Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The National Institutes of Health (NIH) sponsors the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI). These institutes develop cancer drugs.
Some of the major companies in the nscls drugs market are Roche, Novartis, Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly and Company, Takeda Pharmaceutical, Boehringer-Ingelheim, AstraZeneca, Betta Pharmaceuticals, Qilu Oharmaceutical, Pierre Fabre Medicament, Chemo Wanbang Biopharma, Hetero Drugs, Harbin Gloria Pharmaceuticals, Luoxin Pharmaceutical, Teva Pharmaceutical, Mylan, Sun Pharmaceutical, Fosun Pharma, NSCLS Drug.
The nscls drugs market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. NSCLS Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. NSCLS Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. NSCLS Drugs Market - Supply Chain
4.5. Global NSCLS Drugs Market Forecast
4.5.1. NSCLS Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. NSCLS Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. NSCLS Drugs Market Absolute $ Opportunity
5. Global NSCLS Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. NSCLS Drugs Market Size and Volume Forecast by Type
5.3.1. EGFR Targeting
5.3.2. ALK Targeting
5.3.3. PD-1/PD-L1 Targeting
5.3.4. Gemcitabine
5.3.5. Cisplatin/Carboplatin
5.3.6. Pemetrexed
5.3.7. Paclitaxel
5.3.8. Others
5.3.9. NSCLS Drug
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global NSCLS Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. NSCLS Drugs Market Size and Volume Forecast by Application
6.3.1. Less than or equal to 30 Years Old
6.3.2. 31 - 45 Years Old
6.3.3. 46 - 60 Years Old
6.3.4. Above 60 Years Old
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global NSCLS Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. NSCLS Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global NSCLS Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. NSCLS Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global NSCLS Drugs Demand Share Forecast, 2019-2026
9. North America NSCLS Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America NSCLS Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America NSCLS Drugs Market Size and Volume Forecast by Application
9.4.1. Less than or equal to 30 Years Old
9.4.2. 31 - 45 Years Old
9.4.3. 46 - 60 Years Old
9.4.4. Above 60 Years Old
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America NSCLS Drugs Market Size and Volume Forecast by Type
9.7.1. EGFR Targeting
9.7.2. ALK Targeting
9.7.3. PD-1/PD-L1 Targeting
9.7.4. Gemcitabine
9.7.5. Cisplatin/Carboplatin
9.7.6. Pemetrexed
9.7.7. Paclitaxel
9.7.8. Others
9.7.9. NSCLS Drug
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America NSCLS Drugs Demand Share Forecast, 2019-2026
10. Latin America NSCLS Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America NSCLS Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America NSCLS Drugs Market Size and Volume Forecast by Application
10.4.1. Less than or equal to 30 Years Old
10.4.2. 31 - 45 Years Old
10.4.3. 46 - 60 Years Old
10.4.4. Above 60 Years Old
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America NSCLS Drugs Market Size and Volume Forecast by Type
10.7.1. EGFR Targeting
10.7.2. ALK Targeting
10.7.3. PD-1/PD-L1 Targeting
10.7.4. Gemcitabine
10.7.5. Cisplatin/Carboplatin
10.7.6. Pemetrexed
10.7.7. Paclitaxel
10.7.8. Others
10.7.9. NSCLS Drug
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America NSCLS Drugs Demand Share Forecast, 2019-2026
11. Europe NSCLS Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe NSCLS Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe NSCLS Drugs Market Size and Volume Forecast by Application
11.4.1. Less than or equal to 30 Years Old
11.4.2. 31 - 45 Years Old
11.4.3. 46 - 60 Years Old
11.4.4. Above 60 Years Old
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe NSCLS Drugs Market Size and Volume Forecast by Type
11.7.1. EGFR Targeting
11.7.2. ALK Targeting
11.7.3. PD-1/PD-L1 Targeting
11.7.4. Gemcitabine
11.7.5. Cisplatin/Carboplatin
11.7.6. Pemetrexed
11.7.7. Paclitaxel
11.7.8. Others 11.7.9. NSCLS Drug
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe NSCLS Drugs Demand Share, 2019-2026
12. Asia Pacific NSCLS Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific NSCLS Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific NSCLS Drugs Market Size and Volume Forecast by Application
12.4.1. Less than or equal to 30 Years Old
12.4.2. 31 - 45 Years Old
12.4.3. 46 - 60 Years Old
12.4.4. Above 60 Years Old
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific NSCLS Drugs Market Size and Volume Forecast by Type
12.7.1. EGFR Targeting
12.7.2. ALK Targeting
12.7.3. PD-1/PD-L1 Targeting
12.7.4. Gemcitabine
12.7.5. Cisplatin/Carboplatin
12.7.6. Pemetrexed
12.7.7. Paclitaxel
12.7.8. Others
12.7.9. NSCLS Drug
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific NSCLS Drugs Demand Share, 2019-2026
13. Middle East & Africa NSCLS Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa NSCLS Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa NSCLS Drugs Market Size and Volume Forecast by Application
13.4.1. Less than or equal to 30 Years Old
13.4.2. 31 - 45 Years Old
13.4.3. 46 - 60 Years Old
13.4.4. Above 60 Years Old
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa NSCLS Drugs Market Size and Volume Forecast by Type
13.7.1. EGFR Targeting
13.7.2. ALK Targeting
13.7.3. PD-1/PD-L1 Targeting
13.7.4. Gemcitabine
13.7.5. Cisplatin/Carboplatin
13.7.6. Pemetrexed
13.7.7. Paclitaxel
13.7.8. Others
13.7.9. NSCLS Drug
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa NSCLS Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global NSCLS Drugs Market: Market Share Analysis
14.2. NSCLS Drugs Distributors and Customers
14.3. NSCLS Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bristol-Myers Squibb
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Eli Lilly and Company
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Takeda Pharmaceutical
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Boehringer-Ingelheim
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. AstraZeneca
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Betta Pharmaceuticals
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Qilu Oharmaceutical
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pierre Fabre Medicament
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Chemo Wanbang Biopharma
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Hetero Drugs
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Harbin Gloria Pharmaceuticals
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Luoxin Pharmaceutical
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Teva Pharmaceutical
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Mylan
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Sun Pharmaceutical
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Fosun Pharma
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook